Beta Bionic, Inc. (BBNX)

Beta Bionic Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	17.48	26.57	27.68
Short-Term Investments	43.42	70.18	-
Cash & Cash Equivalents	60.9	96.75	27.68
Cash Growth	-	249.58%	-
Receivables	7.46	4.45	-
Inventory	11.29	1.25	-
Other Current Assets	2.9	1.18	0.79
Total Current Assets	82.56	103.62	28.47
Property, Plant & Equipment	-	2.48	3.32
Goodwill and Intangibles	-	3.72	3.55
Other Long-Term Assets	-	0.22	0.19
Total Long-Term Assets	-	6.42	7.06
Total Assets	-	110.04	35.53
Accounts Payable	-	1.17	0.43
Deferred Revenue	-	0.09	-
Current Debt	-	1.22	0.98
Other Current Liabilities	17.88	8.13	7.47
Total Current Liabilities	17.88	10.61	8.87
Long-Term Debt	-	3	3.16
Other Long-Term Liabilities	-	37.83	10.5
Total Long-Term Liabilities	-	40.83	13.65
Total Liabilities	-	51.43	22.53
Total Debt	7.3	4.22	4.13
Debt Growth	-	2.18%	-
Retained Earnings	-	-229.66	-185.57
Comprehensive Income	-	0.14	-
Shareholders' Equity	-228.85	-203.11	-170.03
Net Cash / Debt	53.6	92.52	23.54
Net Cash / Debt Growth	-	293.01%	-
Working Capital	64.68	93.02	19.59

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).